Modified herpes virus joins forces with immunotherapy to attack head and neck tumors
NCT ID NCT07010120
First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study tests a combination of three treatments—immunotherapy (tislelizumab), targeted therapy (afatinib), and a modified herpes virus (lysogenic HSV)—given before surgery for head and neck squamous cell carcinoma. The goal is to see if this approach safely shrinks tumors and improves outcomes. Participants are adults aged 18 to 70 with locally advanced, surgically removable head and neck cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tislelizumab, Afatinib, and lysogenic HSV virus
- What this could lead to
- If successful, this combination could shrink head and neck tumors before surgery, potentially improving survival and reducing the need for more aggressive treatments.
- What could go wrong
- This is an early-phase trial with only 29 participants, so results may not apply broadly. The modified herpes virus and drug combination may cause side effects like immune reactions or organ damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HNSCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Radiation Oncology
Chengdu, Sichuan, 610000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Four-Drug combo erase Triple-Negative breast cancer before surgery?
- Can a One-Two punch of radiation and immunotherapy shrink head and neck tumors before surgery?
- Can a glowing drug light up head and neck tumors?
- Can an AI coach and simple exercises help cancer patients fight frailty?
- Can a Two-Target antibody shrink Hard-to-Treat cancers?
- Can a triple threat of drug, immunotherapy, and radiation wipe out High-Risk urinary tract cancer before surgery?